scholarly journals ZNF282 (Zinc finger protein 282), a novel E2F1 co-activator, promotes esophageal squamous cell carcinoma

Oncotarget ◽  
2014 ◽  
Vol 5 (23) ◽  
pp. 12260-12272 ◽  
Author(s):  
So-Young Yeo ◽  
Sang Yun Ha ◽  
Eun Ji Yu ◽  
Keun-Woo Lee ◽  
Jeong Hoon Kim ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Zinc Finger ◽  
Squamous Cell ◽  
Zinc Finger Protein ◽  
Finger Protein

scholarly journals Hypermethylation of a Cluster of Krüppel-Type Zinc Finger Protein Genes on Chromosome 19q13 in Oropharyngeal Squamous Cell Carcinoma

2011 ◽  
Vol 178 (5) ◽  
pp. 1965-1974 ◽  
Author(s):  
Roberto A. Lleras ◽  
Leslie R. Adrien ◽  
Richard V. Smith ◽  
Benjamin Brown ◽  
Naheed Jivraj ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Zinc Finger ◽  
Squamous Cell ◽  
Zinc Finger Protein ◽  
Oropharyngeal Squamous Cell Carcinoma ◽  
Finger Protein ◽  
Chromosome 19Q13

Salivary zinc finger protein 510 peptide as a novel biomarker for detection of oral squamous cell carcinoma in early stages

2011 ◽  
Vol 412 (15-16) ◽  
pp. 1357-1365 ◽  
Author(s):  
Yu-Jen Jou ◽  
Chia-Der Lin ◽  
Chih-Ho Lai ◽  
Chih-Hsin Tang ◽  
Su-Hua Huang ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Zinc Finger ◽  
Squamous Cell ◽  
Zinc Finger Protein ◽  
Early Stages ◽  
Finger Protein

Resveratrol suppresses malignant progression of oral squamous cell carcinoma cells by inducing the ZNF750 pathway

2021 ◽  
Author(s):  
Yanjun Duan ◽  
Yongjie Wang ◽  
Xiaojia Yin ◽  
Yue Xiao
Keyword(s):  
Squamous Cell Carcinoma ◽  
Growth Factor ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Zinc Finger ◽  
Squamous Cell ◽  
Colony Formation ◽  
Zinc Finger Protein ◽  
Carcinoma Cells ◽  
Finger Protein

Abstract Deletion or mutation of zinc finger protein 750 (ZNF750) has been linked to oral squamous cell carcinoma (OSCC), but it is not clear whether ZNF750 is a therapeutic target for OSCC. This study examined whether activation of zinc finger protein 750 (ZNF750) pathway may be involved in the ability of resveratrol to inhibit malignant progression of CAL-27 oral squamous cell carcinoma cells. CAL-27 cells were treated with resveratrol and transfected with plasmids expressing a ZNF750 mimic or ZNF750 inhibitor. Cell proliferation was assessed using the CCK-8 assay and a BrdU ELISA, and cell cycle distribution and apoptosis were examined using flow cytometry. Colony formation was also assessed. Western blotting was used to examine the effects of resveratrol on levels of angiogenin, vascular endothelial growth factor (VEGF), prolyl hydroxylase 2 (PHD2), G protein signal-regulated protein 5 (RGS5), integrin A5 (ITGA5), integrin B1 (ITGB1), CD44 and ZNF750. Quantitative PCR was used to examine effects on mRNA levels of platelet derived growth factor (PDGFB) and tumor vascular marker CD105. Resveratrol down-regulated angiogenin, VEGF, RGS5, CD105, and the cell adhesion molecules ITGA5, ITGB1 and CD44 in CAL-27 cells. Conversely, it up-regulated ZNF750, PHD2 and PDGFB. These changes were associated with reduced proliferation, reduced colony formation and increased apoptosis. ZNF750 silencing partly reversed these effects of resveratrol. The ability of resveratrol to suppress progression of oral squamous cell carcinoma may involve activation of the ZNF750 pathway and modification of the tumor vascular microenvironment.

scholarly journals Potential Role of Targeting KDR and Proteasome Inhibitors in the Therapy of Esophageal Squamous Cell Carcinoma

2020 ◽  
Vol 19 ◽  
pp. 153303382094806
Author(s):  
Ling Zhang ◽  
Xia Niu ◽  
Yanghui Bi ◽  
Heyang Cui ◽  
Hongyi Li ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Zinc Finger Protein ◽  
Cancer Genomics ◽  
Therapeutic Targets ◽  
Specific Inhibitor ◽  
Genomic Variation ◽  
Tumor Xenograft

Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive cancer types in China. In recent years, progress has been made in various types of cancer genomics including ESCC. However, the clinical significance of genomic variation of ESCC remains poorly defined. In the present study, genomic sequencing data from 469 ESCC cases were analyzed and potential therapeutic targets in the Druggable Genome Interaction Database (DGIdb) were screened. A series of potential therapeutic target genes and pathways were identified, of which treatment of ESCC with bortezomib (a specific inhibitor targeting proteasome) potently inhibited the proliferation of 5 ESCC cell lines and administration of bortezomib led to significant tumor xenograft regression in SCID mice. It was also identified that kinase insert domain receptor (KDR), which had drug recommendations from all 6 sources integrated by the DGldb and harbored significant amplification in ESCC, might be a downstream target of zinc finger protein 750 (ZNF750). ZNF750 acts as a transcription factor and has been demonstrated to harbor frequently inactivating mutations in ESCC by previous independent studies. In the present study, KDR was upregulated upon ZNF750 knockdown and the rescue of ZNF750 also led to marked restoration of KDR. KDR knockdown in stable ZNF750-knockdown KYSE150 and KYSE140 ESCC cells significantly attenuated the promotion of cell growth, colony formation, invasion and migration induced by ZNF750 knockdown. Further experiments found that apatinib treatment, a potent inhibitor of KDR, resulted in profound inhibition of cell proliferation and invasion. Collectively, the present study provided insight for genomic alterations as potential therapeutic targets in ESCC and supported the possibility of a therapeutic strategy targeting the proteasome in ESCC. The present results also suggested that targeting KDR may be an effective way to treat ESCC, not only in KDR variant cases, but also in individuals with ZNF750 mutations and deletions.

Overexpression of Jumonji AT-rich interactive domain 1B and PHD finger protein 2 is involved in the progression of esophageal squamous cell carcinoma

2013 ◽  
Vol 115 (1) ◽  
pp. 56-62 ◽  
Author(s):  
Ling-Ling Sun ◽  
Xing-Xing Sun ◽  
Xiu-E Xu ◽  
Meng-Xiao Zhu ◽  
Zhi-Yong Wu ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Phd Finger ◽  
Finger Protein
Sign in / Sign up

Export Citation Format

Share Document